以苹果黄蚜AphiscitricolavanderGoot为试虫,对金合欢醇和烟碱的联合杀蚜活性进行了测定,以期为开发植物源杀蚜剂产品奠定基础。室内毒力测定采用微量点滴法;田间药效试验参照国家标准进行。金合欢醇和烟碱混用具有明显的杀蚜增效作用,...以苹果黄蚜AphiscitricolavanderGoot为试虫,对金合欢醇和烟碱的联合杀蚜活性进行了测定,以期为开发植物源杀蚜剂产品奠定基础。室内毒力测定采用微量点滴法;田间药效试验参照国家标准进行。金合欢醇和烟碱混用具有明显的杀蚜增效作用,在最佳质量配比(金合欢醇:烟碱=4.82:1)下,共毒系数(CTC)达151.63;经过对溶剂、表面活性剂等助剂的筛选,研制出6%烟碱·金合欢醇可溶液剂,配方为金合欢醇(5%)、烟碱(1%)、表面活性剂(10%)、溶剂(84%),质量检测符合可溶液剂国家质量标准;田间药效试验表明,以126.0 g a.i./hm^2常量喷雾,药后7 d对小麦上的麦长管蚜Sitobion avenae Fabricius和麦二叉蚜Schizaphis graminum(Rondani)混合种群的防效达87.80%,以115.5 g a.i./hm^2常量喷雾,药后7d对苹果黄蚜的防效在81%以上。可见,金合欢醇和烟碱复配具有显著的杀蚜增效作用,具有进一步开发潜力。展开更多
麝香秋葵(Abelmoschus moschatus L. Medicus)又称黄葵,系锦葵科一年生或多年生草本植物,生长在热带、亚热带地区;在我省多分布于南部和西南部,并从1983年开始有了一定规模的人工种植。麝香秋葵籽具有麝香、花香香气,从中提取的精油是...麝香秋葵(Abelmoschus moschatus L. Medicus)又称黄葵,系锦葵科一年生或多年生草本植物,生长在热带、亚热带地区;在我省多分布于南部和西南部,并从1983年开始有了一定规模的人工种植。麝香秋葵籽具有麝香、花香香气,从中提取的精油是一种名贵香料。为新近开发之麝香秋葵籽系列产品的应用提供依据,我们对其精油进行了化学成分分析。展开更多
Trans-trans farnesol (tt-farnesol) is a bioactive sesquiterpene alcohol commonly found in propolis (a beehive product) and citrus fruits, which disrupts the ability of Streptococcus mutans (S. mutans) to form virulent...Trans-trans farnesol (tt-farnesol) is a bioactive sesquiterpene alcohol commonly found in propolis (a beehive product) and citrus fruits, which disrupts the ability of Streptococcus mutans (S. mutans) to form virulent biofilms. In this study, we investigated whether tt-farnesol affects cell-membrane function, acid production and/or acid tolerance by planktonic cells and biofilms of S. mutans UA159. Furthermore, the influence of the agent on S. mutans gene expression and ability to form biofilms in the presence of other oral bacteria (Streptococcus oralis (S. oralis) 35037 and Actinomyces naeslundii (A. naeslundii) 12104) was also examined. In general, tt-farnesol (1 mmol·L-1) significantly increased the membrane proton permeability and reduced glycolytic activity of S. mutans in the planktonic state and in biofilms (P<0.05). Moreover, topical applications of 1 mmol·L-1 tt-farnesol twice daily (1 min exposure/treatment) reduced biomass accumulation and prevented ecological shifts towards S. mutans dominance within mixed-species biofilms after introduction of 1% sucrose. S. oralis (a non-cariogenic organism) became the major species after treatments with tt-farnesol, whereas vehicle-treated biofilms contained mostly S. mutans (>90% of total bacterial population). However, the agent did not affect significantly the expression of S. mutans genes involved in acidogenicity, acid tolerance or polysaccharide synthesis in the treated biofilms. Our data indicate that tt-farnesol may affect the competitiveness of S. mutans in a mixed-species environment by primarily disrupting the membrane function and physiology of this bacterium. This naturally occurring terpenoid could be a potentially useful adjunctive agent to the current anti-biofilm/anti-caries chemotherapeutic strategies.展开更多
Streptococcus mutans is a primary etiological agent of dental caries.Farnesol,as a potential antimicrobial agent,inhibits the development of S.mutans biofilm.In this study,we hypothesized that farnesol inhibits caries...Streptococcus mutans is a primary etiological agent of dental caries.Farnesol,as a potential antimicrobial agent,inhibits the development of S.mutans biofilm.In this study,we hypothesized that farnesol inhibits caries development in vitro and interferes with biofilm fonnation by regulating virulence-associated gene expression.The inhibitory effects of farnesol to S.mutans biofilms on enamel surfaces were investigated by determining micro-hardness and calcium measurements.Additionally,the morphological changes of S.mutans biofilms were compared using field emission scanning electron microscopy and confocal laser scanning microscopy,and the vitality and oxygen sensitivity of S.mutans biofilms were compared using MTT assays.To investigate the molecular mechanisms of farnesol's effects,expressions of possible target genes luxS,brpA,ffh,recA,nth,and smx were analyzed using reverse-transcription polymerase chain reaction(PCR) and quantitative PCR.Farnesol-treated groups exhibited significantly higher micro-hardness on the enamel surface and lower calcium concentration of the supernatants as compared to the-untreated control.Microscopy revealed that a thinner film with less extracellular matrix formed in the farnesol-treated groups.As compared to the-untreated control,farnesol inhibited biofilm formation by 26.4%with500 μmol/L and by 37.1%with 1,000 μmol/L(P< 0.05).Last,decreased transcription levels of luxS,brpA,ffh,recA,nth,and smx genes were expressed in farnesol-treated biofilms.In vitro farnesol inhibits caries development and S.mutans biofilm formation.The regulation of luxS,brpA,ffh,recA,nth,and smx genes may contribute to the inhibitory effects of farnesol.展开更多
The currently used 8%fragrance mix (FM I) does not identify all patients with a positive history of adverse reactions to fragrances. A new FM II with 6 frequently used chemicals was evaluated in 1701 consecutive patie...The currently used 8%fragrance mix (FM I) does not identify all patients with a positive history of adverse reactions to fragrances. A new FM II with 6 frequently used chemicals was evaluated in 1701 consecutive patients patch tested in 6 dermatological centres in Europe. FM II was tested in 3 concentrations-28%FM II contained 5%hydroxyisohexyl 3cyclohexene carboxaldehyde (Lyral.), 2%citral, 5%farnesol, 5%coumarin, 1%citronellol and 10%α-hexyl-cinnamic aldehyde; in 14%FM II, the single constituents’concentration was lowered to 50%and in 2.8%FM II to 10%. Each patient was classified regarding a history of adverse reactions to fragrances:certain, probable, questionable, none. Positive reactions to FM I occurred in 6.5%of the patients. Positive reactions to FMII were dose-dependent and increased from 1.3%(2.8%FM II), through 2.9%(14%FM II) to 4.1%(28%FM II). Reactions classified as doubtful or irritant varied considerably between the 6 centres, with a mean value of 7.2%for FM I and means ranging from 1.8%to 10.6%for FM II. 8.7%of the tested patients had a certain fragrance history. Of these, 25.2%were positive to FM I; reactivity to FM II was again dose-dependent and ranged from 8.1%to 17.6%in this subgroup. Comparing 2 groups of history-certain and none-values for sensitivity and specificity were calculated:sensitivity:FM I, 25.2%; 2.8%FM II, 8.1%; 14%FM II, 13.5%; 28%FM II, 17.6%; specificity:FM I, 96.5%; 2.8%FM II, 99.5%; 14%FM II, 98.8%; 28%FM II, 98.1%. 31/70 patients (44.3%) positive to 28%FMII were negative to FM I, with 14%FM II this proportion being 16/50 (32%). In the group of patients with a certain history, a total of 7 patients were found reacting to FM II only. Conversely, in the group of patients without any fragrance history, there were significantly more positive reactions to FM I than to any concentration of FM II. In conclusion, the new FM II detects additional patients sensitive to fragrances missed by FMI; the number of false-positive reactions is lower with FM II than with FM I. Considering sensitivity, specificity and the frequency of doubtful reactions, the medium concentration, 14%FM II, seems to be the most appropriate diagnostic screening tool.展开更多
A new fragrance mix (FM II), with 6 frequently used chemicals not present in the currently used fragrance mix (FM I), was evaluated in 6 dermatological centres in Europe, as previously reported. In this publication, t...A new fragrance mix (FM II), with 6 frequently used chemicals not present in the currently used fragrance mix (FM I), was evaluated in 6 dermatological centres in Europe, as previously reported. In this publication, test results with the individual constituents and after repeated open application test (ROAT) of FM II are described. Furthermore, cosmetic products which had caused a contact dermatitis in patients were analysed for the presence of the individual constituents. In 1701 patients, the individual constituents of the medium (14%) and the highest (28%) concentration of FM II were simultaneously applied with the new mix at 3 concentrations (break-down testing for the lowest concentration of FM II (2.8%) was performed only if the mix was positive). ROAT was performed with the concentration of the FM II which had produced a positive or doubtful (+or ?+) patch test reaction. Patients’products were ana-lysed for the 6 target compounds by gas chromatography-mass spectrometry (GC-MS). Results:50 patients (2.9%) showed a positive reaction to 14%FM II and 70 patients (4.1%) to 28%FM II. 24/50 (48%) produced a positive reaction to 1 or more of the individual constituents of 14%FM II and 38/70 (54.3%) to 28%FM II, respectively. If doubtful reactions to individual constituents are included, the break-down testing was positive in 74%and 70%, respectively. Patients with a positive reaction to 14%FM II showed a higher rate of reactions to the individual constituent of the 28%FM II:36/50 (72%). Positive reactions to individual constituents in pa-tients negative to FM II were exceedingly rare. If doubtful reactions are regarded as negative, the sensitivity, specificity, positive predictive value and negative predictive value for the medium concentration of FM II towards at least 1 individual constituent was 92.3%(exact 95%confidence interval 74.9-99.1%), 98.4%(97.7-99.0%), 48%(33.7-62.6%) and 99.9%(99.6-100.0%), respectively. For the high concentration, the figures were very similar. The frequency of positive reactions to the individual constituents in descending order was the same for both FM II concentrations:hydroxyisohexyl 3-cyclohexene carboxaldehyde(Lyral.)>citral>farnesol>citronellol >αhexyl-cinnamic aldehyde (AHCA). No unequivocally positive reaction to coumarin was observed. Lyralwas the dominant individualconstituent,with positive reactions in 36%of patients reacting to 14%FM II and 37.1%to 28%FM II. 5/11 patients developed a positive ROAT after a median of 7 days (range 2-10). The 5 patients with a doubtful or negative reaction to 28%FM II were all ROAT negative except 1. There were 7 patients with a certain fragrance history and a positive reaction to either 28%or 14%FM II but a negative reaction to FM I. Analysis with GC-MS in a total of 24 products obtained from 12 patients showed at least 1-5 individual constituents per product:Lyral. (79.2%), citronellol (87.5%), AHCA (58.3%), citral (50%) and coumarin (50%). The patients were patch test positive to Lyral., citral and AHCA. In conclusion, patients with a certain fragrance history and a negative reaction to FMI can be identified by FM II. Testing with individual constituents is positive in about 50%of cases reacting to either 14%or 28%FM II.展开更多
文摘以苹果黄蚜AphiscitricolavanderGoot为试虫,对金合欢醇和烟碱的联合杀蚜活性进行了测定,以期为开发植物源杀蚜剂产品奠定基础。室内毒力测定采用微量点滴法;田间药效试验参照国家标准进行。金合欢醇和烟碱混用具有明显的杀蚜增效作用,在最佳质量配比(金合欢醇:烟碱=4.82:1)下,共毒系数(CTC)达151.63;经过对溶剂、表面活性剂等助剂的筛选,研制出6%烟碱·金合欢醇可溶液剂,配方为金合欢醇(5%)、烟碱(1%)、表面活性剂(10%)、溶剂(84%),质量检测符合可溶液剂国家质量标准;田间药效试验表明,以126.0 g a.i./hm^2常量喷雾,药后7 d对小麦上的麦长管蚜Sitobion avenae Fabricius和麦二叉蚜Schizaphis graminum(Rondani)混合种群的防效达87.80%,以115.5 g a.i./hm^2常量喷雾,药后7d对苹果黄蚜的防效在81%以上。可见,金合欢醇和烟碱复配具有显著的杀蚜增效作用,具有进一步开发潜力。
文摘麝香秋葵(Abelmoschus moschatus L. Medicus)又称黄葵,系锦葵科一年生或多年生草本植物,生长在热带、亚热带地区;在我省多分布于南部和西南部,并从1983年开始有了一定规模的人工种植。麝香秋葵籽具有麝香、花香香气,从中提取的精油是一种名贵香料。为新近开发之麝香秋葵籽系列产品的应用提供依据,我们对其精油进行了化学成分分析。
基金supported by IADR/GSK Innovation in Oral Care Award, USPHS Research grant 1R01DE 018023 from the National Institute of Dental and Craniofacial Research (National Institutes of Health)Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2009-0071090)
文摘Trans-trans farnesol (tt-farnesol) is a bioactive sesquiterpene alcohol commonly found in propolis (a beehive product) and citrus fruits, which disrupts the ability of Streptococcus mutans (S. mutans) to form virulent biofilms. In this study, we investigated whether tt-farnesol affects cell-membrane function, acid production and/or acid tolerance by planktonic cells and biofilms of S. mutans UA159. Furthermore, the influence of the agent on S. mutans gene expression and ability to form biofilms in the presence of other oral bacteria (Streptococcus oralis (S. oralis) 35037 and Actinomyces naeslundii (A. naeslundii) 12104) was also examined. In general, tt-farnesol (1 mmol·L-1) significantly increased the membrane proton permeability and reduced glycolytic activity of S. mutans in the planktonic state and in biofilms (P<0.05). Moreover, topical applications of 1 mmol·L-1 tt-farnesol twice daily (1 min exposure/treatment) reduced biomass accumulation and prevented ecological shifts towards S. mutans dominance within mixed-species biofilms after introduction of 1% sucrose. S. oralis (a non-cariogenic organism) became the major species after treatments with tt-farnesol, whereas vehicle-treated biofilms contained mostly S. mutans (>90% of total bacterial population). However, the agent did not affect significantly the expression of S. mutans genes involved in acidogenicity, acid tolerance or polysaccharide synthesis in the treated biofilms. Our data indicate that tt-farnesol may affect the competitiveness of S. mutans in a mixed-species environment by primarily disrupting the membrane function and physiology of this bacterium. This naturally occurring terpenoid could be a potentially useful adjunctive agent to the current anti-biofilm/anti-caries chemotherapeutic strategies.
基金National Natural Sciences Foundation of China (Grant No.81271151 and Grant No.81371156)Jiangsu Qinglan Project Foundation(2012)The Foundation of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD,2014-37)
文摘Streptococcus mutans is a primary etiological agent of dental caries.Farnesol,as a potential antimicrobial agent,inhibits the development of S.mutans biofilm.In this study,we hypothesized that farnesol inhibits caries development in vitro and interferes with biofilm fonnation by regulating virulence-associated gene expression.The inhibitory effects of farnesol to S.mutans biofilms on enamel surfaces were investigated by determining micro-hardness and calcium measurements.Additionally,the morphological changes of S.mutans biofilms were compared using field emission scanning electron microscopy and confocal laser scanning microscopy,and the vitality and oxygen sensitivity of S.mutans biofilms were compared using MTT assays.To investigate the molecular mechanisms of farnesol's effects,expressions of possible target genes luxS,brpA,ffh,recA,nth,and smx were analyzed using reverse-transcription polymerase chain reaction(PCR) and quantitative PCR.Farnesol-treated groups exhibited significantly higher micro-hardness on the enamel surface and lower calcium concentration of the supernatants as compared to the-untreated control.Microscopy revealed that a thinner film with less extracellular matrix formed in the farnesol-treated groups.As compared to the-untreated control,farnesol inhibited biofilm formation by 26.4%with500 μmol/L and by 37.1%with 1,000 μmol/L(P< 0.05).Last,decreased transcription levels of luxS,brpA,ffh,recA,nth,and smx genes were expressed in farnesol-treated biofilms.In vitro farnesol inhibits caries development and S.mutans biofilm formation.The regulation of luxS,brpA,ffh,recA,nth,and smx genes may contribute to the inhibitory effects of farnesol.
文摘The currently used 8%fragrance mix (FM I) does not identify all patients with a positive history of adverse reactions to fragrances. A new FM II with 6 frequently used chemicals was evaluated in 1701 consecutive patients patch tested in 6 dermatological centres in Europe. FM II was tested in 3 concentrations-28%FM II contained 5%hydroxyisohexyl 3cyclohexene carboxaldehyde (Lyral.), 2%citral, 5%farnesol, 5%coumarin, 1%citronellol and 10%α-hexyl-cinnamic aldehyde; in 14%FM II, the single constituents’concentration was lowered to 50%and in 2.8%FM II to 10%. Each patient was classified regarding a history of adverse reactions to fragrances:certain, probable, questionable, none. Positive reactions to FM I occurred in 6.5%of the patients. Positive reactions to FMII were dose-dependent and increased from 1.3%(2.8%FM II), through 2.9%(14%FM II) to 4.1%(28%FM II). Reactions classified as doubtful or irritant varied considerably between the 6 centres, with a mean value of 7.2%for FM I and means ranging from 1.8%to 10.6%for FM II. 8.7%of the tested patients had a certain fragrance history. Of these, 25.2%were positive to FM I; reactivity to FM II was again dose-dependent and ranged from 8.1%to 17.6%in this subgroup. Comparing 2 groups of history-certain and none-values for sensitivity and specificity were calculated:sensitivity:FM I, 25.2%; 2.8%FM II, 8.1%; 14%FM II, 13.5%; 28%FM II, 17.6%; specificity:FM I, 96.5%; 2.8%FM II, 99.5%; 14%FM II, 98.8%; 28%FM II, 98.1%. 31/70 patients (44.3%) positive to 28%FMII were negative to FM I, with 14%FM II this proportion being 16/50 (32%). In the group of patients with a certain history, a total of 7 patients were found reacting to FM II only. Conversely, in the group of patients without any fragrance history, there were significantly more positive reactions to FM I than to any concentration of FM II. In conclusion, the new FM II detects additional patients sensitive to fragrances missed by FMI; the number of false-positive reactions is lower with FM II than with FM I. Considering sensitivity, specificity and the frequency of doubtful reactions, the medium concentration, 14%FM II, seems to be the most appropriate diagnostic screening tool.
文摘A new fragrance mix (FM II), with 6 frequently used chemicals not present in the currently used fragrance mix (FM I), was evaluated in 6 dermatological centres in Europe, as previously reported. In this publication, test results with the individual constituents and after repeated open application test (ROAT) of FM II are described. Furthermore, cosmetic products which had caused a contact dermatitis in patients were analysed for the presence of the individual constituents. In 1701 patients, the individual constituents of the medium (14%) and the highest (28%) concentration of FM II were simultaneously applied with the new mix at 3 concentrations (break-down testing for the lowest concentration of FM II (2.8%) was performed only if the mix was positive). ROAT was performed with the concentration of the FM II which had produced a positive or doubtful (+or ?+) patch test reaction. Patients’products were ana-lysed for the 6 target compounds by gas chromatography-mass spectrometry (GC-MS). Results:50 patients (2.9%) showed a positive reaction to 14%FM II and 70 patients (4.1%) to 28%FM II. 24/50 (48%) produced a positive reaction to 1 or more of the individual constituents of 14%FM II and 38/70 (54.3%) to 28%FM II, respectively. If doubtful reactions to individual constituents are included, the break-down testing was positive in 74%and 70%, respectively. Patients with a positive reaction to 14%FM II showed a higher rate of reactions to the individual constituent of the 28%FM II:36/50 (72%). Positive reactions to individual constituents in pa-tients negative to FM II were exceedingly rare. If doubtful reactions are regarded as negative, the sensitivity, specificity, positive predictive value and negative predictive value for the medium concentration of FM II towards at least 1 individual constituent was 92.3%(exact 95%confidence interval 74.9-99.1%), 98.4%(97.7-99.0%), 48%(33.7-62.6%) and 99.9%(99.6-100.0%), respectively. For the high concentration, the figures were very similar. The frequency of positive reactions to the individual constituents in descending order was the same for both FM II concentrations:hydroxyisohexyl 3-cyclohexene carboxaldehyde(Lyral.)>citral>farnesol>citronellol >αhexyl-cinnamic aldehyde (AHCA). No unequivocally positive reaction to coumarin was observed. Lyralwas the dominant individualconstituent,with positive reactions in 36%of patients reacting to 14%FM II and 37.1%to 28%FM II. 5/11 patients developed a positive ROAT after a median of 7 days (range 2-10). The 5 patients with a doubtful or negative reaction to 28%FM II were all ROAT negative except 1. There were 7 patients with a certain fragrance history and a positive reaction to either 28%or 14%FM II but a negative reaction to FM I. Analysis with GC-MS in a total of 24 products obtained from 12 patients showed at least 1-5 individual constituents per product:Lyral. (79.2%), citronellol (87.5%), AHCA (58.3%), citral (50%) and coumarin (50%). The patients were patch test positive to Lyral., citral and AHCA. In conclusion, patients with a certain fragrance history and a negative reaction to FMI can be identified by FM II. Testing with individual constituents is positive in about 50%of cases reacting to either 14%or 28%FM II.